Sobrevida a mediano plazo en los pacientes con hipertensión arterial pulmonar en la era de terapias vasodilatadoras específicas del territorio vascular pulmonar

• Sebastián Herrera ^[1] ; Luigi Gabrielli ^[1] ; Alejandro Paredes ^[1] ; Rodrigo Saavedra ^[1] ; María Paz Ocaranza ^[1] ; Pablo Sepúlveda ^[2] ; Hernán Donoso ^[2] ; Leonel López ^[2] ; Hugo Verdejo ^[1] ; Fernando Baraona ^[1] ; Pablo Castro ^[1]
  1. [1] Pontificia Universidad Católica de Chile

     Pontificia Universidad Católica de Chile

     Santiago, Chile

     
  2. [2] Hospital San Juan de Dios

     Hospital San Juan de Dios

     Santiago, Chile

     
• Localización: Revista Médica de Chile, ISSN-e 0034-9887, Vol. 144, Nº. 7, 2016, págs. 829-836
• Idioma: español
• Títulos paralelos:
  • Survival of patients with pulmonary arterial hypertension after the advent of specific pulmonary vasodilator therapies
• Enlaces
  • Texto completo
• Resumen

  • Background: Pulmonary arterial hypertension (PAH) is a rare and progressive disease. Long-term survival remains poor despite of advances in specific vasodilator therapy. Aim: To describe the survival rate in a cohort of PAH patients in two referral centers in Chile. Patients and Methods: One hundred fifteen patients aged 43 ± 15.6 years (85% females) with PAH qualified for this study. Their median pulmonary artery pressure was 55.4 ± 14 mmHg and their six minutes walking capacity was 368 ± 119 m. They were followed for 58 ± 0.4 months and their actual survival rates were compared with the estimated survival using the equation proposed by the French registry of PAH. Results: One, two and three year survival rates were 97, 94 and 89%, respectively. The observed survival rates were greater than the estimated survival. Conclusions: The improvement in survival rates observed in this cohort of patients is similar to what has been described in literature.